Increased Survival Rates for Patients with Glioblastoma Multiforme

Historically, glioblastomas have poor prognosis from diagnosis. The high standard of care and treatment for patients by Northwestern Brain Tumor Institute (NBTI) physicians have led to increased survival of patients with glioblastoma compared to the Surveillance, Epidemiology, and End Results (SEER) Program in terms of length of patient survival post-diagnosis.

The graph below compares the observed survival of NBTI glioblastoma patients diagnosed from 1/1/2004 - 7/1/2012 to the observed survival of glioblastoma referencea patients diagnosed 1/1/2004 - 1/1/2010b.

Studies of patients with glioblastoma have shown that a patient’s likelihood of surviving an additional year increase for every year they are alive, with aggressive approaches leading to a larger proportion of patients surviving beyond two years post-diagnosis.

View the 2011 Northwestern Brain Tumor Outcomes Data

NBTI physicians provide specialized care, offer unparalleled clinical expertise, and initiate leading-edge clinical trials for the treatment of glioblastoma multiforme and other brain tumors.


Search NBTI Clinical Trials

 

Facebook Facebook You Tube